| # | Drug | Count |
|---|---|---|
| 0 | QUETIAPINE | 24 |
| 1 | ACETAMINOPHEN | 23 |
| 2 | PANCRELIPASE | 22 |
| 3 | FENTANYL | 21 |
| 4 | ACETAMINOPHEN 500MG | 19 |
| 5 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 19 |
| 6 | IBUPFROFEN | 19 |
| 7 | IBUPROFEN | 19 |
| 8 | IBUPROFEN 200 MG | 19 |
| 9 | IBUPROFEN 200MG | 19 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CAMPHOR, EUCALYPTUS OIL, MENTHOL | 1 | 0.0043 |
| 1 | AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, OXYBENZONE | 1 | 0.0042 |
| 2 | DORAVIRINE | 2 | 0.0025 |
| 3 | AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE | 1 | 0.0022 |
| 4 | AMISULPRIDE | 10 | 0.0016 |
| 5 | IDARUCIZUMAB | 2 | 0.0014 |
| 6 | TIGECYCLINE | 4 | 0.0006 |
| 7 | CLOBAZAM | 10 | 0.0006 |
| 8 | PANCRELIPASE | 22 | 0.0006 |
| 9 | ACETAMINOPHEN AND CODEINE PHOSPHATE | 1 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nonsteroidal Anti-inflammatory Drug [EPC] | 38 |
| 1 | Benzodiazepine [EPC] | 32 |
| 2 | GLP-1 Receptor Agonist [EPC] | 26 |
| 3 | Opioid Agonist [EPC] | 23 |
| 4 | Corticosteroid [EPC] | 22 |
| 5 | Atypical Antipsychotic [EPC] | 19 |
| 6 | Insulin Analog [EPC] | 19 |
| 7 | HMG-CoA Reductase Inhibitor [EPC] | 15 |
| 8 | Vitamin C [EPC] | 14 |
| 9 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 12 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Humanized Monoclonal Antibody Fragment [EPC] | 2 | 0.0014 |
| 1 | Dopamine-2 Receptor Antagonist [EPC] | 10 | 0.0013 |
| 2 | Tetracycline-class Antibacterial [EPC] | 4 | 0.0005 |
| 3 | mu-Opioid Receptor Agonist [EPC] | 1 | 0.0003 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 3 | 0.0001 |
| 5 | Provitamin D2 Compound [EPC] | 4 | 0.0001 |
| 6 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 3 | 0.0001 |
| 7 | Echinocandin Antifungal [EPC] | 1 | 0.0001 |
| 8 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 12 | 0.0001 |
| 9 | Vitamin K [EPC] | 1 | 0.0001 |